Core Viewpoint - The company has successfully passed the preliminary formal review of the drug application for PTS (Toluene Sulfonamide Injection) by the National Healthcare Security Administration, but this does not guarantee inclusion in the national basic medical insurance catalog or commercial insurance innovative drug catalog [1] Group 1 - The drug application materials for PTS have passed the initial formal review by the National Healthcare Security Administration [1] - The review ensures that the submitted drug meets the application criteria and verifies the completeness and standardization of the application materials [1] - Further steps, including expert review and negotiation, are required before the drug can be included in the insurance catalog [1]